Here's what Paine Webber said last week about scrips and market share:
Solid monthly scrips for June
ú For the month of June 1998, Viracept prescriptions
were as follows:
- Total prescriptions were 49,801 compared with
48,087 in May (3.6% unadjusted growth, -2.5%
adjusted growth)
- New prescriptions were 17,955 compared with
17,756 in May (1.1% unadjusted growth, -5.0%
adjusted growth)
- Refills were 31,846 compared with 30,331 in
May (5.0% unadjusted growth, -1.1% adjusted
growth).
ú Viracept continues to gain market share (see
Chart 2). Viracept has increased its market share from
31.3% in May to 31.8% in June for total prescriptions
within the protease inhibitor class. As we have been
anticipating, Viracept continues to close the gap with
Crixivan. In our analysis, total Crixivan scrips have
declined by 9% year over year. Its market share has
dropped considerably relative to last summer (55-
60%). For the period from May to June, Crixivan's
market share in total scrips has dropped to 33.6%
from 33.9%. |
